ReNeuron’s recent clinical update was encouraging and highlighted an increased focus on its retinal pipeline. We view the decision to put the critical limb ischaemia (CLI) programme on hold as sensible and look forward to FDA feedback for the group’s Phase III stroke trial in due course. We update our forecasts and valuation this morning, remaining at Buy with a 9p Target Price.
27 Apr 2017
N+1 Singer - ReNeuron Group - Increased focus on retinal pipeline
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Increased focus on retinal pipeline
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
27 Apr 2017 -
Author:
Sheena Berry -
Pages:
7
ReNeuron’s recent clinical update was encouraging and highlighted an increased focus on its retinal pipeline. We view the decision to put the critical limb ischaemia (CLI) programme on hold as sensible and look forward to FDA feedback for the group’s Phase III stroke trial in due course. We update our forecasts and valuation this morning, remaining at Buy with a 9p Target Price.